Retinitis Pigmentosa Hastalığında Transkorneal Elektrik Stimülasyonu ve Trombositten Zengin Plazma Terapileri

Retinitis pigmentosa hastalığının bugün için kesin bir tedavisi bulunmamaktadır. Son zamanlarda, tedavi sürecinde transkorneal elektrik stimülasyonu ve trombositten zengin plazma terapileri klinik pratikte yer almaya başlamıştır. Umut veren bu terapilerin ana hedefleri hastalığın ilerleyişini yavaşlatmak, görme fonksiyonlarını korumak ve artırmaktır. Sunulan derleme bu terapiler hakkında güncel bilgiler içermektedir.

Transcorneal Electrical Stimulation and Platelet Rich Plasma Therapies in Retinitis Pigmentosa Disease

There is no cure for Retinitis Pigmentosa disease today. Recently, transcorneal electrical stimulation and platelet-rich plasma therapies have begun to take place in clinical practice during the treatment process. The main goals of these promising therapies are to slow the progression of the disease, to protect and increase visual functions. Presented review includes current informationes about these therapies.

Kaynakça

Harton DT, Berson EI, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-1809.

Parmeggiani F. Clinics, epidemiology and genetics of retinitis pigmentosa. Curr Genomics. 2011;12(4):236-237.

Guadagni V, Novelli E, Piano I, Gargini C, Strettoi E: Pharmacological approaches to retinitis pigmentosa: a laboratory perspective. Prog Retin Eye Res. 2015;48:62-81.

Gregory-Evans K, Weleber RG, Pennesi ME, Retinitis pigmentosa and allied disorders. In: Schachat AP, ed. Ryan’s Retina, 6th ed. Philadelphia: Elsevier; 2018;861.

Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–860.

Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol. Ther. 2013;21(3):509–519.

Sahel JA, Roska B. Gene therapy for blindness. Annu. Rev. Neurosci. 2013;36:467-488.

Garg SJ, Federman J: Optogenetics, visual prosthesis and electrostimulation for retinal dystrophies. Curr Opin Ophthalmol. 2013;24(5):407-414.

Özmert E, Arslan U. Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Research & Therapy. 2020;11(1):25.

Sheludchenko VM, Budzinskaya MV, Ronzina IA, Smirnova TV. Effectiveness of new techniques of intraocular stem cells transplantation in the treatment of retinitis pigmentosa. Vestn Oftalmol. 2019;135(5):267-271.

Mills JO, Jalil A, Stanga PE. Electronic retinal implants and artificial vision: journey and present. Eye. 2017;31(10):1383–1398.

Luo YHL, da Cruz L. The Argus II retinal prosthesis system. Prog Retin Eye Res. 2016;50:89–107.

Stingl K, Zrenner E. Electronic approaches to restitute vision in patients with neurodegenerative diseases of the retina. Ophthalmic Res. 2013;50(4):215-220.

Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA. 2006;103(10):3896–3901.

Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122(9):1297–1305.

Bahrami H, Melia M, Dagnelie G. Lutein supplementation in retinitis pigmentosa: PC- based vision assessment in a randomized double-masked placebo-controlled clinical trial. BMC Ophthalmol. 2006;6:23.

Kumar A, Midha N, Gogia V, Gupta S, Sehra S, Chohan A. Efficacy of oral valproic acid in patients with retinitis pigmentosa. J. Ocul. Pharmacol. Ther. 2014;30(7):580-586.

Tawada A, Sugawara T, Ogata, K, Hagiwara A, Yamamoto S. Improvement of central retinal sensitivity six months after topical isopropyl unoprostone in patients with retinitis pigmentosa. Indian J. Ophthalmol. 2013;61(3):95-99.

Schatz A, Röck T, Naycheva L, Willmann G, Wilhelm B, Peters T, et al. Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Invest Ophthalmol Vis Sci. 2011;52(7):4485–4496.

Schatz A, Pach J, Gosheva M, Naycheva L, Willmann G, Wilhelm B, et al. Transcorneal Electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled follow-up study over 1 year. Invest Ophthalmol Vis Sci. 2017;58(1):257–269.

Kahraman NS, Oner A. Effect of Transcorneal Electrical Stimulation on Patients with Retinitis Pigmentosa. J Ocul Pharmacol Ther. 2020;36(8):609-617.

Arslan U, Özmert E, Demirel S, Örnek F, Şermet F. Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2018;256(5):893-908.

Kahraman NS, Oner A. Subtenon Injection of Autologous Platelet-Rich Plasma in Retinitis Pigmentosa: Is It a New Therapeutic Option? Open Journal of Ophthalmology. 2020;10(1): 77-88.

Koenekoop RK. Why some photoreceptors die, while others remain dormant: lessons from RPE65 and LRAT associated retinal dystrophies. Ophthalmic Genet. 2011;32(2):126–128.

Wang W, Lee SJ, Scott PA, Lu X, Emery D, Liu Y, et al. Two-step reactivation of dormant cones in retinitis pigmentosa. Cell Rep 2016;15(2):372–385.

Dor H: Beiträge zur Electrotherapie der Augenkrankheiten. Albrecht von Graefes Arch Klin Exp Ophthalmol. 1873;19:532.

Sabel BA, Fedorov AB, Naue N, Borrmann A, Herrmann C, Gall C. Non-invasive alternating current stimulation improves vision in optic neuropathy. Restor Neurol Neurosci. 2011;29(6):493-505.

Gall C, Fedorov AB, Ernst L, Borrmann A, Sabel BA. Repetitive transorbital alternating current stimulation in optic neuropathy. Neurorehabilitation. 2010;27(4):335-341.

Anastassiou G, Schneegans AL, Selbach M, Kremmer S: Transpalpebral electrotherapy for dry age-related macular degeneration (AMD): an exploratory trial. Restor Neurol Neurosci. 2013;31(5):571-578.

Chaikin L, Kashiwa K, Bennet M, Papastergiou G, Gregory W: Microcurrent stimulation in the treatment of dry and wet macular degeneration. Clin Ophthalmol (Auckland, NZ). 2015;9:2345-2353.

Sehic A, Guo S, Cho KS, Corraya RM, Chen DF, Utheim TP. Electrical Stimulation as a Means for Improving Vision.Am J Pathol. 2016 Nov;186(11):2783-2797.

Dawson WW, Trick GL, Litzkow CA. Improved electrode for electroretinography. Invest Ophthalmol Vis Sci. 1979;18(9):988–991.

Fu L, Lo AC, Lai JS, Shih KC. The role of electrical stimulation therapy in ophthalmic diseases. Graefes Arch Clin Exp Ophthalmol. 2015; (2):171-6.

Tao Y, Chen T, Liu B, Wang LQ, Peng GH, Qin LM et al. .The transcorneal electrical stimulation as a novel therapeutic strategy against retinal and optic neuropathy: a review of experimental and clinical trials.Int J Ophthalmol. 2016;9(6):914-9.

Wagner SK, Jolly JK, Pefkianaki M, Gekeler F, Webster AR, Downes SM, Maclaren RE. Transcorneal electrical stimulation for the treatment of retinitis pigmentosa: results from the TESOLAUK trial. BMJ Open Ophthalmol. 2017;2(1):e000096.

Ota Y, Ozeki N, Yuki K, Shiba D, Kimura I, Tsunoda K, et al.The Efficacy of Transcorneal Electrical Stimulation for the Treatment of Primary Open-angle Glaucoma: A Pilot Study.Keio J Med. 2018;25;(3):45-53.

Fujikado T, Morimoto T, Matsushita K, Shimojo H, Okawa Y, Tano Y. Effect of transcorneal electric stimulation in patients with nonarteritic ischemic optic neuropathy or traumatic optic neuropathy. Jpn J Ophthalmol. 2006;50(3):266-73.

Inomata K, Shinoda K, Ohde H, Tsunoda K, Hanazono G, Kimura I, et al. Transcorneal electrical stimulation of retina to treat longstanding retinal artery occlusion. 2007;245(12):1773-80.

Ozeki N, Shinoda K, Ohde H , Ishida S, Tsubota K. Improvement of visual acuity after transcorneal electrical stimulation in case of Best vitelliform macular dystrophy. 2013; 251(7):1867-70.

Morimoto T, Miyoshi T, Matsuda S, Tano Y, Fujikado T, Fukuda Y. Transcorneal electrical stimulation rescues axotomized retinal ganglion cells by activating endogenous retinal IGF-1 system. Invest Ophthalmol Vis Sci. 2005;46(6):2147-55.

Morimoto T, Miyoshi T, Fujikado T, Tano Y, Fukuda Y. Electrical stimulation enhances the survival of axotomized retinal ganglion cells in vivo. Neuroreport. 2002;13(2):227-30.

Henrich-Noack P, Voigt N, Prilloff S, Fedorov A, Sabel BA. Transcorneal electrical stimulation alters morphology and survival of retinal ganglion cells after optic nerve damage. Neurosci Lett. 2013;543:1-6.

Brushart TM, Hoffman PN, Royall RM, Murinson BB, Witzel C, Gordon T. Electrical stimulation promotes motoneuron regeneration without increasing its speed or conditioning the neuron. 2002; 22(15): 6631-6638.

Morimoto T, Fujikado T, Choi JS, Kanda H, Miyoshi T, Fukuda Y, Tano Y. Transcorneal electrical stimulation promotes the survival of photoreceptors and preserves retinal function in royal college of surgeons rats. Invest Ophthalmol Vis Sci. 2007;48(10):4725-32.

Morimoto T, Kanda H, Kondo M, Terasaki H, Nishida K, Fujikado T. Transcorneal electrical stimulation promotes survival of photoreceptors and improves retinal function in rhodopsin P347L transgenic rabbits. Invest Ophthalmol Vis Sci. 2012;53(7):4254-61.

Ni YQ, Gan DK, Xu HD, Xu GZ, Da CD. Neuroprotective effect of transcorneal electrical stimulation on light-induced photoreceptor degeneration. Exp Neurol. 2009;219(2):439–452.

Sato T, Lee TS, Takamatsu F, Fujikado T. Induction of fibroblast growth factor-2 by electrical stimulation in cultured retinal Mueller cells. Neuroreport. 2008; 29;(16):1617-21.

Sato T, Fujikado T, Morimoto T, Matsushita K, Harada T, Tano Y. Effect of electrical stimulation on IGF-1 transcription by L-type calcium channels in cultured retinal Müller cells. Jpn J Ophthalmol. 2008;52(3):217-223.

Kolomeyer AM and Zarbin MA. Trophic Factors in the Pathogenesis and Therapy for Retinal Degenerative Diseases. Survey of Ophthalmology. 2014;59(2):134-165.

Wang X, Mo X, Li D, Wang Y, Fang Y, Rong X et al. Neuroprotective effect of transcorneal electrical stimulation on ischemic damage in the rat retina. Exp Eye Res. 2011;93(5):753–760.

Kurimoto T, Oono S, Oku H, Tagami Y, Kashimoto R, Takata M. et al. Transcorneal electrical stimulation increases chorioretinal blood flow in normal human subjects. Clin Ophthalmol. 2010;6:1441-6.

Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. 2003;76(4):463-471.

Zhang C, Shen JK, Lam TT, Zeng HY, Chiang SK, Yang F, Tso MO. Activation of microglia and chemokines in light-induced retinal degeneration. Mol Vis. 2005;11:887-95.

Ling L, Gao F, Zhang Q, He T, Zhao Y, Xing Y, et al. Optical Coherence Tomography Angiography Assessed Retinal and Choroidal Microvasculature Features in Patients with Retinitis Pigmentosa: A Meta-Analysis. Biomed Res Int. 2019;6723917.

Miura G, Sugawara T, Kawasaki Y, Tatsumi T, Nizawa T, Baba T et al. Clinical Trial to Evaluate Safety and Efficacy of Transdermal Electrical Stimulation on Visual Functions of Patients with Retinitis Pigmentosa. Sci Rep. 2019;9(1):11668.

Gekeler F, Messias A, Ottinger M, Bartz-Schmidt KU, Zrenner E. Phosphenes electrically evoked with DTL electrodes: a study in patients with retinitis pigmentosa, glaucoma, and homonymous visual field loss and normal subjects. Invest Ophthalmol Vis Sci. 2006;47(11):4966-74.

Naycheva L, Schatz A, Röck T, Willmann G, Messias A, Bartz-Schmidt KU et al. Phosphene thresholds elicited by transcorneal electrical stimulation in healthy subjects and patients with retinal diseases. Invest Ophthalmol Vis Sci. 2012;53(12):7440-8.

Morimoto T, Miyoshi T, Sawai H, Fujikado T. Optimal parameters of transcorneal electrical stimulation (TES) to be neuroprotective of axotomized RGCs in adult rats. Exp Eye Res. 2010;90(2):285-91.

Miyake K, Yoshida M, Inoue Y, Hata Y. Neuroprotective effect of transcorneal electrical stimulation on the acute phase of optic nerve injury. Invest Ophthalmol Vis Sci. 2007;48(5):2356-61.

Okazaki Y, Morimoto T, Sawai H. Parameters of optic nerve electrical stimulation affecting neuroprotection of axotomized retinal ganglion cells in adult rats. Neurosci Res. 2008;61(2):129-35.

Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb. Haemost. 2004; 91(1):4-15.

Anitua E, Muruzabal F, Tayebba A, Riestra A, Perez VL, Merayo-Lloves J, Orive G. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93(8):605-14.

Alio JL, Arnalich-Montiel F, Rodriguez AE. The Role of “Eye Platelet Rich Plasma” (E-Prp) for Wound Healing in Ophthalmology. Current Pharmaceutical Biotechnology. 2012;13(7):1257–1265.

Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, Corrêa do Amaral RJ, Granjeiro JM, Borojevic R. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(67):1-13.

Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, Andia I. Effectiveness of autologous preparation-rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed. Mat. Res. B. 2008;84(2):415-421.

Sánchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intraarticular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin. Exp. Rheumatol. 2008; 26(5):910-913.

Garg AK, Gargenese D, Peace I. Using platelet-rich plasma to develop an autologous membrane for growth factor delivery in dental implant therapy. Dent. Implantol. Update. 2000;11(6):41-44.

Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast. Reconstr. Surg. 2001;107(1):229-237.

Mishra A, Harmon K, Woodall J, Vieira A. Sports Medicine Applications of Platelet Rich Plasma. Curr Pharm Biotechnol. 2012;13(7):1185-95.

Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of sites for implants. Int. J. Oral Maxillofac. Implants. 1999;14(4):529-535.

Anitua, E. The use of plasma-rich growth factors (PRGF) in oral surgery. Pract Proced Aesthet Dent. 2001;13(6):487-493.

Anitua, E, Sánchez M, Orive G, Andía I. The potential effects of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials, 2007;28(31):4551-4560.

Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007;114(7):1286-1293.

Alio, J.L, Colecha JR, Pastor S, Rodriguez A, Artola A. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic. Res. 2007;39(3):124-129.

Pâques M, Chastang C, Mathis A, Sahel J. Massin P. Dosquet C, et al. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology. 1999;106(5):932-938.

Vick VL, Holds JB, Hartstein ME, Rich RM, Davidson BR. Use of Autologous Platelet Concentrate in Blepharoplasty Surgery. Ophthalmic Plastic & Reconstructive Surgery. 2006;22(2):102–104.

Özmert E, Arslan A. Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet-Rich Plasma: Preliminary Clinical Results. Advances in Therapy . 2019; 36(9):2273–2286.

Reed GL, Fitzgerald ML, Polgar J: Molecular mechanisms of platelet exocytosis: insights into the secrete life of thrombocytes. Blood. 2000;96(10):3334–3342.

Blair P, Flaumenhaft R. Platelet alpha- granules: basic biology and clinical correlates. Blood Rev. 2009;23(4):177–189.

Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006; 24(5):227-234.

Nurden AT, Nurden P, Sánchez M, Andía I, Anitua E. Platelets and wound healing. Front. Biosci. 2008;13: 3532-3548.

Marx R.E. Platelet-rich plasma: evidence to support its use. J. Oral Maxillofac. Surg. 2004;62(8):489-496.

Senzel L, Gnatenko DV, Bahou WF: The platelet proteome. Curr Opin Hematol 2009;16(5):329–333.

Anitua E, Sanchez M, Merayo-Lloves J, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-induced myodifferentiation. Invest Ophthalmol Vis Sci. 2011;52(9): 6066–6073.

Le G, Kaux JF, Seidel L, Péters P, Gothot A, Albert A, Crielaard JM: Étude comparative de cinq techniques de préparation plaquettaire (platelet-rich plasma). Pathol Biol. 2011;59(3):157–160.

Castillo TN, Pouliot MA, Kim HJ, Dragoo JL: Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2010;39(2):266–271.

Weibrich G, Hansen T, Klies W, Buch R, Hitzler WE: Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone. 2004;34(4):665–671.

Kawasumi M, Kitoh H, Siwicka KA, Ishiguro N: The effect of the platelet concentration in platelet-rich plasma gel on the regeneration of bone. J Bone Joint Surg Br. 2008;90(7):966–972.

McCarrel TM, Minas T, Fortier LA: Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am. 2012;94(19):1–8.

Mazzocca AD, McCarthy MBR, Chowaniec DM, Cote MP, Romeo AA, Bradley JP, et al. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012;94(4):308–316.

Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-228.

Anitua E, Alkhraisat MH, Orive G. Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J Control Release. 2012;157(1): 29–38.

Anitua E, Muruzabal F, Pino A, Merayo-Lloves J, Orive G. Biological stability of plasma rich in growth factors eye drops after storage of 3 months. Cornea. 2013; 32(10):1380–1386.

Arslan U, Özmert E. Management of Retinitis Pigmentosa via Platelet-Rich Plasma or Combination with Electromagnetic Stimulation: Retrospective Analysis of 1-Year Results.Adv Ther. 2020;37(5):2390-2412.

Drago L, Bortolin M, Vassena C, Taschieri S, Del Fabbro M: Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol 2013;13:47–51.

Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, Desiderio MA: Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. J Cell Physiol 2010;225(3):757–766.

Randelli P, Arrigoni P, Ragone V, Aliprandi A, Cabitza P: Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up. J Shoulder Elbow Surg. 2011;20(4):518–528.

Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V, Jacobs CR: Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods. 2009;15(3):431–435

Kaynak Göster